Physician profile
Alan Bullock
NPI 1033101712
$342.28
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $309 · 2020: $32.85.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $126.55 | 2019 | |
| Novartis Pharmaceuticals Corporation | $79.96 | 2019 | |
| Amgen INC. | $44.35 | 2019-2020 | |
| Pacira Therapeutics, INC. | $17.57 | 2019 | |
| Daiichi Sankyo INC. | $13.55 | 2019 | |
| Zyla Life Sciences, INC. | $13.42 | 2019 | |
| Stimwave Technologies Incorporated | $11.93 | 2019 | |
| Lilly USA, LLC | $11.93 | 2020 | |
| Grt US Holding, INC. | $11.69 | 2019 | |
| Stryker Corporation | $11.33 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Bullock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.